Oncocyte Corp Files S-1 for Securities Registration
Ticker: IMDX · Form: S-1 · Filed: Mar 28, 2025 · CIK: 1642380
Sentiment: neutral
Topics: s-1, registration, sec-filing
TL;DR
Oncocyte Corp just filed an S-1. Looks like they're prepping for a stock offering.
AI Summary
Oncocyte Corporation filed an S-1 form on March 28, 2025, indicating a registration for securities. The company, incorporated in California with its principal executive offices at 15 Cushing, Irvine, CA 92618, operates in the in vitro & in vivo diagnostic substances sector. Joshua Riggs is listed as the President and Chief Executive Officer.
Why It Matters
This S-1 filing signals Oncocyte Corporation's intent to raise capital or undergo a significant corporate action involving its securities, which could impact its stock price and future operations.
Risk Assessment
Risk Level: medium — S-1 filings often precede stock offerings or significant corporate changes, which carry inherent market risks and uncertainties.
Key Numbers
- 2835 — SIC Code (Industry classification for 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES')
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- 20250328 (date) — Filing Date
- 15 Cushing Irvine, California 92618 (address) — Principal Executive Offices
- Joshua Riggs (person) — President and Chief Executive Officer
- 333-286251 (registration_number) — SEC File Number
FAQ
What is the primary purpose of this S-1 filing for Oncocyte Corporation?
The S-1 filing is a registration statement filed with the SEC, typically to register securities for a public offering or other significant corporate actions.
When was this S-1 filing submitted to the SEC?
The filing was submitted as of March 28, 2025.
Who is the principal executive officer of Oncocyte Corporation mentioned in the filing?
Joshua Riggs is listed as the President and Chief Executive Officer.
What is Oncocyte Corporation's primary business sector according to the filing?
The company is classified under 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' with SIC code 2835.
Where are Oncocyte Corporation's principal executive offices located?
The principal executive offices are located at 15 Cushing, Irvine, California 92618.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on March 28, 2025 by Joshua Riggs regarding Oncocyte Corp (IMDX).